How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Table 4 Prevalence of non-advanced adenoma and colorectal neoplasia within the target group

	Combination of DM2 and SCORE ≥ 10 (n = 157)	SCORE ≥ 10 (n = 413)	DM2 (n = 156)	P value1
Adenoma, n	69	211	66	0.33
(%, 95%CI)	(44%, 36%-52%)	(51%, 46%-56%)	(42%, 34%-50%)
Advanced adenoma, n	25	89	17	< 0.05
(%, 95%CI)	(16%, 11%-23%)	(22%, 18%-26%)	(11%, 6%-17%)
Cancer, n	3	5	3	0.56
(%, 95%CI)	(2%, 0%-5%)	(1%, 0%-3%)	(2%, 0%-6%)

¹P value was obtained using a likelihood ratio test. The comparison models were adjusted for age, sex and previous FIT+ (fecal immunochemical test positivity). DM2: Type 2 diabetes mellitus; SCORE: Systematic COronary Risk Evaluation.